YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc. (“MOLCURE”), an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. […]
BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform
Accelerating the development of highly specific antibodies against pHLA targets to fight cancer. – The development of highly specific T cell engagers directed against pHLA tumor targets will be quick and easy. – BioCopy’s innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. – […]
